• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Insilico’s Potential Best-in-Class AI Drug for Sought-After Cancer Target

by Syed Hamza Sohail 02/15/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • InSilico Medicine, a clinical-stage company utilizing generative artificial intelligence (AI) for drug discovery, reveals the development of an orally bioavailable preclinical candidate compound. This compound targets KIF18A and aims to treat advanced solid tumors characterized by TP53 mutation.
  • The development is particularly significant for high-grade serous ovarian cancer (HGSOC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).

Advancing Cancer Therapeutics with Innovative AI-Driven Strategies

Chromosomal instability (CIN) is a defining characteristic of cancer, resulting from persistent errors in chromosome segregation during cell division. KIF18A, a motor protein essential for mitosis, has emerged as a potential target for therapeutic intervention in CIN-related cancers. ISM9682, a highly selective inhibitor of KIF18A developed by InSilico Medicine, demonstrates promising preclinical efficacy. Through the utilization of Chemistry42, InSilico’s generative chemistry engine, ISM9682 was identified from a series of novel macrocyclic structures. 

Preclinical studies reveal ISM9682’s broad anti-tumor activity across HGSOC, TNBC, and NSCLC CIN cell lines, along with favorable pharmacokinetic properties and safety profile. InSilico plans to explore combination therapies with DNA repair inhibitors like Olaparib and expand into wider indications. Leveraging AI and human expertise, InSilico has established a robust pipeline, with 17 preclinical candidates nominated since 2021 and five progressing to clinical stages. The company has also secured major global out-licensing agreements, including partnerships with Exelixis and Menarini in 2023. Furthermore, InSilico introduced significant updates to its Pharma.AI platform in November 2023, featuring the innovative Copilot feature, enhancing the synergy between large language models and proprietary AI frameworks.

“Targeting KIF18A to inhibit CIN cancers is an emerging therapeutic strategy in drug discovery with broad clinical prospects,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “It is exciting that our team discovered a distinct molecule with desirable safety and promising efficacy using Chemistry42. As the IND-enabling study progresses, we are looking forward to identifying the best indication and advancing the program to the clinical stage.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |